Cargando…

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load

Disclosure: M. Godlewska: None. A. Boguslawska: None. A. Grochowska: None. A. Hubalewska-Dydejczyk: None. A. Gilis-Januszewska: None. Introduction: Clinical, pathophysiological and prognostic significance of different patterns of growth hormone response in oral glucose tolerance test (OGTT) has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godlewska, Magdalena, Boguslawska, Anna, Grochowska, Anna, Hubalewska-Dydejczyk, Alicja, Gilis-Januszewska, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology And Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554126/ http://dx.doi.org/10.1210/jendso/bvad114.1144

Ejemplares similares

Diverse Manifestation of Acromegaly With Suspicion of Ectopic GHRH Secretion. Report of Two Cases
por: Godlewska, Magdalena, et al.
Publicado: (2021)

THU099 The Challenging Management Of Silent Corticotroph PitNET—From Very Aggressive To Mild Course Of Disease During Long Follow Up
por: Bogusławska, Anna, et al.
Publicado: (2023)

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function
por: Minasyan, Mari, et al.
Publicado: (2023)

One Fourth of Adult Patients With Acromegaly Have Tall Stature With Similar Frequency in Males And Females
por: Bogusławska, Anna, et al.
Publicado: (2021)

Intrasellar Cavernous Hemangioma, a Rare Condition Causing Both Radiological And Clinical Difficulties- a Case Report
por: Nowak, Andrzej Jerzy, et al.
Publicado: (2021)

FRI320 The Various Clinical Outcomes Of Giant Prolactinomas In Men
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2023)

Pituitary Stalk Lesions - Single Center Long Term Observation
por: Kluczynski, Lukasz, et al.
Publicado: (2021)

Testing of Adrenal Axis Function in Patients With Combined Pituitary Hormone Deficiency Caused by PROP1 Mutation
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2021)

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

THU065 Evaluation Of Sarcopenia And Bone Health In Patients With Acromegaly
por: Eroglu, Imdat, et al.
Publicado: (2023)

THU060 Time To First Remission, Medical Therapy And Survival In Acromegaly: UK Acromegaly Register (UKAR) Study
por: Deshmukh, Harshal, et al.
Publicado: (2023)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly
por: Falch, Camilla Maria, et al.
Publicado: (2023)

MON-300 AIP Gene Germline Mutations in Non-Selected Patients with Apparently Sporadic Pituitary Macrodenomas
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

THU059 Increased Intracellular And Extracellular Myocardial Masses On Cardiac Magnetic Resonance Imaging In Patents With Acromegaly
por: Wolf, Peter, et al.
Publicado: (2023)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
por: de Herder, Wouter W, et al.
Publicado: (2023)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

THU068 Evaluation Of Nonalcoholic Fatty Liver Disease, Liver Fibrosis And Serum Angiopoietin-like Protein Levels In Patients With Acromegaly
por: Eroglu, Imdat, et al.
Publicado: (2023)

THU028 Novel Approach To Management Of Acromegaly With De Novo Oral Octreotide Or Combination Therapy With Cabergoline: A Case Series
por: Halstrom, Amanda, et al.
Publicado: (2023)

THU077 Differences In Clinicopathological Features Of Acidophil Stem Cell Adenomas Compared To Other Subtypes Of Acromegaly: A Retrospective Study
por: Ji Yuen, Kevin Choong, et al.
Publicado: (2023)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

SUN-LB078 Biochemically Controlled Acromegaly Patients on a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice Still Remain Symptomatic: Preliminary Results from Endocrinology Health Care Professionals
por: Geer, Eliza, et al.
Publicado: (2019)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

SAT-265 An Asynchronous Double Growth Hormone Secreting Pituitary Adenoma as a Cause of Rapid Tumor Regrowth After Initially Successful Surgery
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
por: Sowa-Staszczak, Anna, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4058sv47prr9lpv40dus43glj1